| 名稱 | CXCR3/β-Arrestin/CHO GPCR細(xì)胞 |
| 型號 | CBP71397 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | CXCR3/β-Arrestin/CHO GPCR細(xì)胞 |
產(chǎn)品搜索
相關(guān)文章
- CD74-ROS1的藥靶模型+DNARNA標(biāo)準(zhǔn)品+ddPCR試劑盒
- 談?wù)勀[瘤細(xì)胞為何對抑制生長信號不敏感
- ATCC細(xì)胞株開發(fā)的四階段簡介
- ?LILRB4細(xì)胞篩選模型
- 【產(chǎn)品推介】TMB診斷標(biāo)準(zhǔn)品
- 上海細(xì)胞中心分享細(xì)胞分裂后的三種情況
- 【連載-Toll樣受體系列2】TLR7激動劑藥物細(xì)胞篩選模型
- AVβ6靶點(diǎn)細(xì)胞篩選模型
- 大腦中新發(fā)現(xiàn)的一種淋巴細(xì)胞，能夠清除大腦廢物
- 【靶點(diǎn)模型+診斷質(zhì)控】BCR-ABL1的藥物開發(fā)和診斷
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > GPCR細(xì)胞株 > CBP71397CXCR3/β-Arrestin/CHO GPCR細(xì)胞
- 詳細(xì)內(nèi)容
| CBP71397 | |
| I. Background | |
| CXCR3 (C-X-C Motif Chemokine Receptor 3) is a Protein Coding gene. Diseases associated with CXCR3 include Cutaneous Lupus Erythematosus and Pulmonary Sarcoidosis. Among its related pathways are CCR5 Pathway in Macrophages and Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions. Gene Ontology (GO) annotations related to this gene include G protein-coupled receptor activity and chemokine receptor activity. | |
| II. Introduction | |
| Host Cell: | CHO |
| Stability: | 20 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | F12k+10%FBS+5ug/ml puromycin+5ug/ml blasticidin |
| Mycoplasma Status: | Negative |
| Storage: | Liquid nitrogen immediately upon delivery |
| Application(s): | Functional assay for CXCR3 receptor |
| Transducer: | β-arrestin |
| Ⅲ. Description of Host Cell Line | |
| Organism: | Hamster |
| Tissue: | Ovary |
| Morphology: | Epithelial |
| Growth Properties: | Adherent |
| Ⅳ. Representative Data | |
Figure 1. Recombinant CXCR3/β-Arrestin/CHO constitutively expressing CXCR3. | |
Figure 2.Dose response of Human CXCL11 in CXCR3 β-Arrestin CHO-K1 Cell Line (C5). | |
